T1	Participants 57 79	Dutch randomised FAMTX
T2	Participants 87 124	The Dutch Gastric Cancer Group (DGCG)
T3	Participants 256 293	patients with operable gastric cancer
T4	Participants 496 724	Patients younger than 75 years of age with a good physical and mental condition and a histologically proven adenocarcinoma of the stomach without clinical or radiographic (computed tomography scan) evidence of distant metastases
T5	Participants 755 810	Early gastric cancer or cardia carcinoma were excluded.
T6	Participants 1259 1389	56 eligible and evaluable patients were entered: 27 were randomised to receive FAMTX before surgery and 29 to undergo surgery only
